Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00784303 | Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology | completed | Phase 2 | 117 | Eisai Inc.INDUSTRY | 6 | Apr 22, 2020 | clinicaltrials |
| NCT03211117 | Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | completed | Phase 2 | 66 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01013597 | Trial of LBH589 in Metastatic Thyroid Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02084732 | Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study | completed | Phase 2 | 35 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02390934 | Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer(RAD-THYR) | completed | Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00181168 | Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer | completed | Phase 2 | 63 | Johns Hopkins UniversityOTHER | 2 | Nov 2, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT01025453 | Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT01182285 | A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | May 16, 2018 | clinicaltrials |
| NCT00098345 | Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | May 7, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02114658 | Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients | completed | Phase 2 | 18 | BayerINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00358956 | A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | completed | Phase 2 | 19 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT00559949 | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2017 | clinicaltrials |
| NCT01083550 | Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer | completed | Phase 2 / Phase 3 | 74 | University Health Network, TorontoOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02515084 | Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma(THYRIRMTEP) | completed | Phase 2 | 37 | Centre Henri BecquerelOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT01625520 | SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer | completed | Phase 2 | 19 | Federico II UniversityOTHER | 1 | Apr 25, 2016 | clinicaltrials |
| NCT01137097 | Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC(LSLNB) | completed | Phase 2 / Phase 3 | 278 | Samsung Medical CenterOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT00123760 | Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer | completed | Phase 2 / Phase 3 | 10,838 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01173289 | Study of External Beam Radiotherapy to Thyroid Carcinoma | completed | Phase 2 | 62 | National Cancer Center, KoreaOTHER_GOV | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01964144 | An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer | completed | Phase 2 | 40 | Yonsei UniversityOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00134043 | Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00098813 | Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT02055989 | A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx | completed | Phase 1 / Phase 2 | 105 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 5, 2014 | clinicaltrials |
| NCT00389441 | Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | completed | Phase 2 | 52 | PfizerINDUSTRY | 9 | Nov 25, 2013 | clinicaltrials |
| NCT00121628 | A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 184 | AmgenINDUSTRY | 0 | Oct 9, 2013 | clinicaltrials |
| NCT00251316 | Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer | completed | Phase 2 | 34 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00094055 | Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer | completed | Phase 2 | 60 | PfizerINDUSTRY | 1 | Jun 26, 2012 | clinicaltrials |
| NCT01616316 | Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients | completed | Phase 2 / Phase 3 | 86 | Samsung Medical CenterOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00279721 | Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer. | completed | Phase 2 | 40 | Alberta Health servicesOTHER | 0 | Jan 19, 2012 | clinicaltrials |
| NCT00176748 | Treatment for Patients With Metastatic Thyroid Cancer | completed | Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 15, 2010 | clinicaltrials |
| NCT00887107 | Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma | completed | Phase 2 | 32 | Leiden University Medical CenterOTHER | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00080574 | The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients | completed | Phase 2 | 20 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Apr 22, 2020source: clinicaltrials